BACKGROUND: Limited information about the epidemiology of hepatitis C virus (HCV) infection is available in Puerto Rico, one of the areas hardest hit by the human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) epidemic. We estimated the prevalence of HCV infection and identified correlates of seropositivity in the municipality of San Juan, Puerto Rico. METHODS: A probability cluster design was employed to select a sample of households representative of the population aged 21-64 years in San Juan during 2001-2002. All 964 subjects completed a face-to-face interview to gather data on demographics and self-reported risk behaviours followed by venipuncture for HCV antibody testing. Variables that were at least marginally associated with HCV seroprevalence (P < 0.10) in the bivariate analyses were considered for inclusion into the multiple logistic regression model to estimate the adjusted prevalence odds ratio (POR). RESULTS: Overall weighted prevalence of HCV infection was 6.3% (95% CI 3.6-10.9%). A significant (P < 0.05) higher prevalence was observed among subjects with the following characteristics: age 30-49 (9.5%), male sex (10.6%), < or =12 years of education (9.6%), no health coverage (12.6%), lifetime heroin use (39.2%), lifetime cocaine use (39.6%), tattooing practices (34.2%), history of imprisonment (32.8%), and self-reported histories of hepatitis B virus infection (30.4%) and HIV/AIDS (92.1%). Multivariate logistic regression revealed that tattooing practices (POR = 8.9; 95% CI 1.7-44.7), lifetime cocaine use (POR = 5.5; 95% CI 2.2-13.5), blood transfusions prior to 1992 (POR = 4.0; 95% CI 1.6-10.1), lifetime heroin use (POR = 3.3; 95% CI 1.4-7.8), and history of imprisonment (POR = 2.3; 95% CI 1.1-4.9) remained significantly associated with HCV seropositivity. CONCLUSIONS: The large prevalence of HCV infection observed in Puerto Rican adults residing in San Juan suggest that HCV infection is an emerging public health concern and merits further investigation.
BACKGROUND: Limited information about the epidemiology of hepatitis C virus (HCV) infection is available in Puerto Rico, one of the areas hardest hit by the human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) epidemic. We estimated the prevalence of HCV infection and identified correlates of seropositivity in the municipality of San Juan, Puerto Rico. METHODS: A probability cluster design was employed to select a sample of households representative of the population aged 21-64 years in San Juan during 2001-2002. All 964 subjects completed a face-to-face interview to gather data on demographics and self-reported risk behaviours followed by venipuncture for HCV antibody testing. Variables that were at least marginally associated with HCV seroprevalence (P < 0.10) in the bivariate analyses were considered for inclusion into the multiple logistic regression model to estimate the adjusted prevalence odds ratio (POR). RESULTS: Overall weighted prevalence of HCV infection was 6.3% (95% CI 3.6-10.9%). A significant (P < 0.05) higher prevalence was observed among subjects with the following characteristics: age 30-49 (9.5%), male sex (10.6%), < or =12 years of education (9.6%), no health coverage (12.6%), lifetime heroin use (39.2%), lifetime cocaine use (39.6%), tattooing practices (34.2%), history of imprisonment (32.8%), and self-reported histories of hepatitis B virus infection (30.4%) and HIV/AIDS (92.1%). Multivariate logistic regression revealed that tattooing practices (POR = 8.9; 95% CI 1.7-44.7), lifetime cocaine use (POR = 5.5; 95% CI 2.2-13.5), blood transfusions prior to 1992 (POR = 4.0; 95% CI 1.6-10.1), lifetime heroin use (POR = 3.3; 95% CI 1.4-7.8), and history of imprisonment (POR = 2.3; 95% CI 1.1-4.9) remained significantly associated with HCV seropositivity. CONCLUSIONS: The large prevalence of HCV infection observed in Puerto Rican adults residing in San Juan suggest that HCV infection is an emerging public health concern and merits further investigation.
Authors: Lilliana Morales-Vásquez; Edgar I Miranda-Avalo; José R Rodríguez-Medina; Yomarid Quiñones-Badillo; Juan Marqués-Lespier; José Muñoz-Acabá; Rafael Pastrana; Cynthia M Pérez-Cardona; Yasuhiro Yamamura; Esther A Torres Journal: P R Health Sci J Date: 2014-12 Impact factor: 0.705
Authors: Ana Patricia Ortiz; Marievelisse Soto-Salgado; Erick Suárez; María del Carmen Santos-Ortiz; Guillermo Tortolero-Luna; Cynthia M Pérez Journal: J Sex Med Date: 2011-06-15 Impact factor: 3.802
Authors: Melissa Welch-Lazoritz; Patrick Habecker; Kirk Dombrowski; Angelica Rivera Villegas; Carmen Ana Davila; Yadira Rolón Colón; Sandra Miranda De León Journal: Int J Drug Policy Date: 2017-02-01
Authors: Marisol Peña-Orellana; Adriana Hernández-Viver; Glorimar Caraballo-Correa; Carmen E Albizu-García Journal: J Health Care Poor Underserved Date: 2011-08
Authors: Mark H Kuniholm; Molly Jung; James E Everhart; Scott Cotler; Gerardo Heiss; Geraldine McQuillan; Ryung S Kim; Howard D Strickler; Bharat Thyagarajan; Marston Youngblood; Robert C Kaplan; Gloria Y F Ho Journal: J Infect Dis Date: 2014-01-13 Impact factor: 5.226
Authors: Carlos Romero Marrero; Ana P Ortiz; Cynthia M Pérez; Javier Pérez; Esther A Torres Journal: P R Health Sci J Date: 2009-06 Impact factor: 0.705